Ramucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): pooled results from two phase 3 studies (REACH and REACH-2)
Matthias Pinter, Masatoshi Kudo, RS Finn, M Morimot, K.-M. Rau, Masafumi Ikeda, Chia‐Jui Yen, Peter R. Galle, Josep M. Llovet, Bruno Daniele, Howard J. Lim, Khoon Lin Ling, Kazuko Yamaguchi‐Shinozaki, Reigetsu Yoshikawa, C Wang, Paolo Abada, Ryan C. Widau, Andrew X. Zhu (2020). Ramucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): pooled results from two phase 3 studies (REACH and REACH-2). Zeitschrift für Gastroenterologie, DOI: 10.1055/s-0040-1712319.
